Next Thursday’s event brings together four London listed companies with huge potential.

ANGLE (LON:AGL), Rightster (LON:RTSR), Clinigen (LON:CLIN) Venn Life Sciences (LON:VENN) have plenty of exciting nearterm newsflow.
Make sure you don’t miss out on July 2 by securing your place HERE.

ANGLE is a medtech company with pioneering products in cancer diagnostics and foetal health. The company’s flagship product is the Parsortix cell separation system which is designed to capture very rare cells from blood.

It has just received Chinese and Australian patents while patents covering a number of other major markets are expected in the short-medium term. Chief executive Andrew Newland will be here to discuss the investment proposition in more depth.

Elsewhere, online video specialist Rightster is a global video network for distribution, content-sourcing, audience engagement and monetisation.
Rightster extends the reach of videos to web, mobile and connected audiences via social channels, portals, platforms, online newspapers, magazines and blogs as well as its own YouTube network.

Management’s confidence in the company was recently underlined as certain directors and senior managers subscribed for shares in the firm worth a total of £110,000. Chief Executive Patrick Walker will be at the forum to detail how he intends to drive growth from within the company.
Elsewhere, Clinigen is a rapidly-growing speciality pharmaceutical and services company which is focused on the growing trend of personalised medicine. Its three divisions are “Clinical Trial Services”, “Global Access Programs” and “Specialty Pharmaceuticals”, allowing the company to operate efficiently in a complex global regulatory environment.

Management feels that the latest deal to manage the global access programme for a new lung cancer drug will see it service a high level of unmet medical need across the globe. Chief operating officer Shaun Chilton will be at the conference to explain the potential significance of this deal. 

Finally, Venn Life Sciences provides clinical trial management to pharmaceutical, biotechnology, medical device and academic organisations. In the most recent vindication of the company’s strategy of increasing its footprint in Europe, the company recently secured a €2 million contract for the management of phase III trials in rheumatology which will cover multiple European countries.

The new deal comes after the company reported a 140% revenue increase in 2014 as well as €4.1 million of new contracts in March this year with a US based biotechnology company. Chief Executive Officer Tony Richardson will update investors…..

Please join us at 5:45pm to allow for a prompt 6pm start. Each company has 20 minutes to give a short presentation and then 10 minutes QA. This will be followed by the ‘Champagne Raffle’ where six guests will win a bottle each.

The event will be rounded off with a drinks reception with canapés.